Novo Nordisk Reports Results of Tresiba (insulin degludec) in CONCLUDE Study for Type 2 Diabetes

 Novo Nordisk Reports Results of Tresiba (insulin degludec) in CONCLUDE Study for Type 2 Diabetes

Novo Nordisk Reports Results of Tresiba (insulin degludec) in CONCLUDE Study for Type 2 Diabetes

Shots:

  • The CONCLUDE study assess the hypoglycemic risk with Tresiba (qd) vs insulin glargine U300 (qd) in 1,609 patients with T2D with/out oral anti-diabetic drugs, for 36wks. maintenance period and a total treatment period of up to 88wks.
  • The CONCLUDE study result: reduction in the rate of severe hypoglycemia & nocturnal symptomatic hypoglycemia (80% & 37% vs 62% & 43%) during maintenance period & total treatment period, reduction in the overall risk of hypoglycemia and significantly lower HbA1c, required insulin dose (67U vs 73U)
  • Tresiba is basal insulin, providing a duration of action beyond 42hrs. with a flat and stable glucose-lowering effect, received first regulatory approval in Sept’2012 and is approved therapy in 80+ countries globally

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post